dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Klouvas, G. D. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Mylonakis, N. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Klouvas, G. D. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Samantas, E. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Mylonakis, N. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:04Z | |
dc.date.available | 2018-06-22T09:54:04Z | |
dc.date.issued | 1997 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42174 | |
dc.description.abstract | This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether an intensified dose-carboplatin could yield a better response. Carboplatin at a dose of 450 mg/m2 dose in combination with vindesine 3 mg/m2 every three weeks and GM-CSF support was used in a phase II study to treat 44 patients with non-small cell lung cancer (NSCLC). As compared to our previous study carboplatin dose intensity was increased from 75 mg/m2/wk to 150 mg/m2/wk. Six patients (13.6%) responded to treatment and all were partial responders. The median duration of response was 5 months (range 1.5-9 month). After a retrospective analysis a dose response effect was not evident at different carboplatin AUC doses. Twenty patients (45.45%) experienced thrombocytopenia and seventeen patients (38.6%) anemia as major toxicities. This study shows that in NSCLC a dose-response effect does not exist between carboplatin dose intensification and response rate cannot be traced. | en |
dc.language.iso | eng | en |
dc.source | Journal of Experimental and Clinical Cancer Research | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Carboplatin | en |
dc.subject | Priority journal | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Subcutaneous drug administration | en |
dc.subject | Granulocyte macrophage colony stimulating factor | en |
dc.subject | Non-small-cell lung | en |
dc.subject | Vindesine | en |
dc.subject | Nsclc | en |
dc.subject | Dose-intensification | en |
dc.subject | Gm-csf | en |
dc.subject | Granulocyte-macrophage colony-stimulating factor | en |
dc.title | Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG) | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 16 | |
dc.description.issue | 1 | |
dc.description.startingpage | 91 | |
dc.description.endingpage | 94 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |